Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q9P2E3
UPID:
ZNFX1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9P2E3; Q9BQM7; Q9BQM8; Q9H8C1; Q9H9S2; Q9NUM1; Q9NWW1
Background:
NFX1-type zinc finger-containing protein 1 plays a pivotal role in antiviral defense mechanisms. It functions as a sensor for double-stranded RNA, recognizing viral RNA to initiate the type I interferon response. This protein is also crucial for immunity against certain bacteria, including mycobacteria.
Therapeutic significance:
Given its involvement in immunodeficiency 91 and hyperinflammation, targeting NFX1-type zinc finger-containing protein 1 offers a promising avenue for therapeutic intervention. Enhancing its function could mitigate the severe symptoms associated with this disorder, including recurrent infections and systemic hyperinflammation.